Diabetes Drug Market Research Report – Global Forecast to 2023

Diabetes Drug Market Research Report – Global Forecast to 2023

ID: MRFR/HC/0654-HCRR | January, 2018 | Region: Global | 80 pages | Half-Cooked Research Reports

Global Diabetes Drug Market Research Report, Type of Diabetes (Type-1 And Type-2), By Administration (Oral, Intravenous, Other), By Drug Class (Insulin, Sensitizers, SGLT-2 Inhibitors, Alpha-Glucosidase Inhibitors), By End Users (Hospital & Clinics, Ambulatory Clinics) - Forecast to 2023


Market Scenario


Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two type of diabetes namely type-1 diabetes and type-2 diabetes. During last decade there is a tremendous increase in the number of diabetic population. According to International Diabetes Federation, in 2016, it was estimated that 420 million adult population were suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. A number of different types of drugs are available in the market however, no available treatment can cure diabetes totally. The global diabetic drug market is majorly driven by increasing number of diabetic population. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. To meet the increasing demand for the drugs government of different countries are providing support to manufacturers. Increasing government support will help to boost the market in coming future. However, cost issues, strict regulatory rules and long approval time for drugs may led to restrain the growth of the market.


The global diabetes drug market is expected to grow at a CAGR of 6.38% during forecasted period.


 


Intended Audience



  • Government and Private Hospitals

  • Blood banks and institutes

  • Biotechnological institutes

  • Pharmaceutical companies

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories  


Figure 1:- Global diabetes drug market share, by region

diabetes drug market


Sources: WHO, annual reports, press release, white paper, and company presentation


Segmentation


The global diabetes drug market is segmented on the basis of types, route of administration, drug class, and end users.


On the basis of types, the market is segmented into type-1 diabetes and type-2 diabetes.


On the basis of route of administration, the market is segmented into oral, intravenous and other.


On the basis of drug class they are insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, secretagogues, peptide analogs and others. Sensitizers are sub segmented into thiazolidinediones and biguanides. Secretagogues are further segmented into sulfonylureas and non-sulfonylureas


On the basis of end users, the market is segmented into hospital & clinics, ambulatory clinics and other. 


Regional Analysis


America dominates the global diabetes drug market owing to large diabetic patient population. According to the WHO, in 2016, 9.6% of total America population were suffering from diabetes. In addition to this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. Increasing cholesterol level and smoking increases the possibility of causing diabetes. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US had diagnosed with high cholesterol level. Furthermore, increasing awareness among the people regarding different monitoring procedures, rising awareness and well-developed technology have also contributed to the growth of the market.


Europe accounts for the second largest diabetes drug market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market in Europe.


Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and increasing need for the better treatment.


On the other hand, the Middle East & Africa has the least share in the global diabetes drug market due to presence of poor economy especially in Africa region. Middle East holds the major share in the Middle East & Africa diabetes drug market owing to well-developed healthcare sector and huge healthcare expenditure. 


Research Methodology


Diabetes Drug Market-


Sources: WHO, annual reports, press release, white paper, and company presentation


 


Key Players for global diabetes drug market


The major player in the global diabetic drug market are Eli Lilly (US), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Biocon (US), Sunpharma (India), Sanofi (France), Novartis (Switzerland), Merck & Co. (US), Pfizer (US), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), Takeda (Japan)




TABLE OF CONTENT    

Chapter 1.    Report Prologue    

Chapter 2.    Market Introduction  
 

      2.1    Definition    

      2.2    Scope of the Study    

            2.2.1    Research Objective    

            2.2.2    Assumptions    

            2.2.3    Limitations    

Chapter 3.    Research Methodology

      3.1    Introduction

      3.2    Primary Research    

      3.3    Secondary research    

      3.4    Market Size Estimation

Chapter 4.    Market Dynamics

      4.1    Drivers    

      4.2    Restrains

      4.3    Opportunities    

      4.4    Challenges

      4.5    Macroeconomic Indicators

      4.6    Technology Trends & Assessment            

Chapter 5.    Market Factor Analysis

      5.1    Porters Five Forces Analysis

            5.1.1    Bargaining Power of Suppliers    

            5.1.2    Bargaining Power of Buyers

            5.1.3    Threat of New Entrants    

            5.1.4    Threat of Substitutes    

            5.1.5    Intensity of Rivalry    

      5.2    Value Chain Analysis

      5.3    Investment Feasibility Analysis    

      5.4    Pricing Analysis

Chapter 6.    Global Diabetes Drug Market, by Type

     6.1    Introduction

      6.2    Type-1 Diabetes

Market Estimates & Forecast, 2017 – 2023

      6.3    Type-2 Diabetes

Market Estimates & Forecast, 2017 – 2023

Chapter 7.    Global Diabetes Drug Market, by Administration

    7.1    Introduction

      7.2    Oral

Market Estimates & Forecast, 2017 – 2023

      7.3    Intravenous

Market Estimates & Forecast, 2017 – 2023

      7.4    Others

Chapter 8    Global Diabetes Drug Market, by End User

      8.1    Introduction

      8.2    Insulin 

Market Estimates & Forecast, 2017 – 2023

      8.3    Sensitizers

Market Estimates & Forecast, 2017 – 2023

      8.4    SGLT-2 Inhibitors

Market Estimates & Forecast, 2017 – 2023

      8.5    Alpha-Glucosidase Inhibitors

Market Estimates & Forecast, 2017 – 2023

Chapter 9    Global Diabetes Drug Market, by End User

      9.1    Introduction

      9.2    Hospitals & Clinics

Market Estimates & Forecast, 2017 – 2023

      9.3    Ambulatory Clinics

Market Estimates & Forecast, 2017 – 2023

      9.4    Others

Market Estimates & Forecast, 2017 – 2023

Chapter 10.    Global Diabetes Drug Market, by Region

      10.1    Introduction

      10.2    America

            10.2.1    North America

                10.2.1.1    US

                10.2.1.1    Canada

            10.2.2    South America

      10.3    Europe

            10.3.1    Western Europe

                10.3.1.1    Germany

                10.3.1.2    France

                10.3.1.3    Italy

                10.3.1.4    Spain

                10.3.1.5    UK

                10.3.1.6    Rest of Western Europe

            10.3.2    Eastern Europe

      10.4    Asia Pacific

            10.4.1    Japan

            10.4.2    China

            10.4.3    India

            10.4.4    Australia

            10.4.5    Republic of Korea

            10.4.6    Rest of Asia Pacific

      10.5    The Middle East & Africa

            10.5.1    United Arab Emirates

            10.5.2     Saudi Arabia

            10.5.3    Oman

            10.5.4    Kuwait

            10.5.5    Qatar

            10.5.6    Rest of the Middle East & Africa

Chapter 11    Company Landscape    

      11.1    Introduction    

      11.2    Market Share Analysis    

      11.3    Key Development & Strategies    

            11.3.1    Key Developments    

Chapter 12    Company Profiles    

      12.1    Eli Lilly      

            12.1.1    Company Overview    

            12.1.2    Product Overview    

            12.1.3    Financials    

            12.1.4    SWOT Analysis    

      12.2    AstraZeneca     

            12.2.1    Company Overview    

            12.2.2    Product Overview    

            12.2.3    Financial Overview    

            12.2.4    Key Developments    

            12.2.5    SWOT Analysis    

      12.3    Abbott     

            12.3.1    Company Overview    

            12.3.2    Product Overview    

            12.3.3    Financial Overview

            12.3.4    Key Development    

            12.3.5    SWOT Analysis    

      12.4     Biocon 

            12.4.1    Company Overview    

            12.4.2    Product/Business Segment Overview    

            12.4.3    Financial Overview    

            12.4.4    Key Development    

            12.4.5    SWOT Analysis    

      12.5    Sunpharma

            12.5.1    Company Overview    

            12.5.2    Product Overview    

            12.5.3    Financial overview    

            12.5.4    Key Developments    

      12.6    Merck & Co., Inc.    

            12.6.1    Company Overview    

            12.6.2    Product Overview    

            12.6.3    Financial Overview    

            12.6.4    Key Developments    

      12.7    GlaxoSmithKline plc 

            12.7.1    Overview    

            12.7.2    Product Overview    

            12.7.3    Financials    

            12.7.4    Key Developments    

            12.7.5    SWOT Analysis    

    12.8    Others

Chapter 13    MRFR Conclusion    

      13.1    Key Findings    

            13.1.1    From CEO’s View Point    

            13.1.2    Unmet Needs of the Market    

      13.2    Key Companies to Watch    

      13.3    Prediction of Pharmaceutical industry

Chapter 14    Appendix



LIST OF TABLES

Table 1        Diabetes Drug Industry Synopsis, 2017 – 2023

Table 2        Global Diabetes Drug Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3        Global Diabetes Drug Market by Region, 2017 – 2023, (USD Million)

Table 4        Global Diabetes Drug Market by Types, 2017 – 2023, (USD Million)

Table 5        Global Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 6        Global Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 7        Global Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 8        North America Diabetes Drug Market by Types, 2017 – 2023, (USD Million)

Table 9        North America Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 10    North America Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 11    North America Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 12    US Market by Types, 2017 – 2023, (USD Million)

Table 13    US Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 14    US Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 15    US Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 16    Canada Market by Types, 2017 – 2023, (USD Million)

Table 17    Canada Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 18    Canada Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 19    Canada Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 20    South America Market by Types, 2017 – 2023, (USD Million)

Table 21    South America Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 22    South America Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 23    South America Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 24    Europe Market by Types, 2017 – 2023, (USD Million)

Table 25    Europe Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 26    Europe Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 27    Europe Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 28    Western Europe Market by Types, 2017 – 2023, (USD Million)

Table 29    Western Europe Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 30    Western Europe Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 31    Eastern Europe Market by Types, 2017 – 2023, (USD Million)

Table 32    Eastern Europe Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 33    Eastern Europe Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 34    Eastern Europe Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 35    Asia Pacific Market by Types, 2017 – 2023, (USD Million)

Table 36    Asia Pacific Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 37    Asia Pacific Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 38    Asia Pacific Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 39    Middle East & Africa Market by Types, 2017 – 2023, (USD Million)

Table 40    Middle East & Africa Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 41    The Middle East & Africa Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 42    Middle East & Africa Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)



LIST OF FIGURES

Figure 1    Research Process

Figure 2    Segmentation for Global Diabetes Drug Market

Figure 3    Segmentation Market Dynamics for Global Diabetes Drug Market

Figure 4    Global Diabetes Drug market Share, by Type 2016

Figure 5    Global Diabetes Drug market Share, by Administration 2016

Figure 6    Global Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Figure 7    Global Diabetes Drug Market Share, by End Users, 2016

Figure 8    Global Diabetes Drug Market Share, by Region, 2016

Figure 9    North America Diabetes Drug Market Share, by Country, 2016

Figure 10    Europe Diabetes Drug Market Share, by Country, 2016

Figure 11    Asia Pacific Diabetes Drug Market Share, by Country, 2016

Figure 12    Middle East & Africa Diabetes Drug Market Share, by Country, 2016

Figure 13    Global Diabetes Drug Market: Company Share Analysis, 2016 (%)

Figure 14    Eli Lilly: Key Financials

Figure 15    Eli Lilly: Segmental Revenue

Figure 16    Eli Lilly: Geographical Revenue

Figure 17    AstraZeneca: Key Financials

Figure 18    AstraZeneca: Segmental Revenue

Figure 19    AstraZeneca: Geographical Revenue 

Figure 20    Abbott: Key Financials

Figure 21    Abbott: Segmental Revenue

Figure 22    Abbott: Geographical Revenue

Figure 23    Sunpharma: Key Financials

Figure 24    Sunpharma: Segmental Revenue

Figure 25    Sunpharma: Geographical Revenue

Figure 26    Merck & Co., Inc.: Key Financials

Figure 27    Merck & Co., Inc.: Segmental Revenue

Figure 28    Merck & Co., Inc.: Geographical Revenue

Figure 29    GlaxoSmithKline plc: Key Financials

Figure 30    GlaxoSmithKline plc: Segmental Revenue

Figure 31    GlaxoSmithKline plc: Geographical Revenue

Figure 32    Sanofi: Key Financials

Figure 33    Sanofi: Segmental Revenue

Figure 34    Sanofi: Geographical Revenue